Candel Therapeutics, Inc. (NASDAQ:CADL) CEO Paul Peter Tak Sells 22,528 Shares

Candel Therapeutics, Inc. (NASDAQ:CADL) CEO Paul Peter Tak sold 22,528 shares of the stock in a transaction that occurred on Wednesday, July 17th. The stock was sold at an average price of $6.47, for a total transaction of $145,756.16. Following the completion of the transaction, the chief executive officer now owns 330,735 shares in the company, valued at $2,139,855.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Paul Peter Tak also recently made the following trade(s):

• On Thursday, July 11th, Paul Peter Tak sold 20,293 shares of Candel Therapeutics stock. The stock was sold at an average price of $5.97, for a total value of $121,149.21.

Candel Therapeutics Price Performance

NASDAQ CADL opened at $6.01 on Monday. The business’s fifty day moving average is $7.73 and its 200 day moving average is $4.74. Candel Therapeutics, Inc. has a fifty-two week low of $0.66 and a fifty-two week high of $14.30. The company has a debt-to-equity ratio of 1.66, a quick ratio of 2.00 and a current ratio of 2.00. The company has a market capitalization of $178.83 million, a PE ratio of -4.70 and a beta of -0.95.

Candel Therapeutics (NASDAQ:CADL) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.28) earnings per share for the quarter. Sell-side analysts predict that Candel Therapeutics, Inc. will post -0.91 earnings per share for the current year.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.